Showing results (581-590 of 652) with videos related to

Sort By:
Pageof 66
Blood|March 17, 2011
Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLCLaurent Sutton, Sylvie Chevret, Olivier Tournilhac, et al.
Blood|April 18, 2014
Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemiaKheira Beldjord, Sylvie Chevret, Vahid Asnafi, et al.
Pediatric Research|December 26, 2018
Recommendations for the design of therapeutic trials for neonatal seizuresJanet S Soul, Ronit Pressler, Marilee Allen, et al.
Blood|May 16, 2018
Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 studyRegis Peffault de Latour, Sylvie Chevret, Charlotte Jubert, et al.
The Journal of Investigative Dermatology|August 28, 2017
STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer NetworkJulie Delyon, Sylvie Chevret, Thomas Jouary, et al.
Therapeutic Innovation & Regulatory Science|November 24, 2025
In Silico Clinical Trials in Drug Development: A Systematic ReviewBohua Chen, Lucia Chantal Schneider, Christian Röver, et al.
Eclinicalmedicine|July 15, 2024
Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort studyAlizée Bozonnat, Marie Beylot-Barry, Olivier Dereure, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2021
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)Thomas Cluzeau, Marie Sebert, Ramy Rahmé, et al.
Eclinicalmedicine|December 25, 2024
Erratum: Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort studyAlizée Bozonnat, Marie Beylot-Barry, Olivier Dereure, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2022
Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trialMarie Véron, Sylvie Chevret, Jean-Jacques Grob, et al.
Pageof 66